Insulin Glulisine in Healthy Lean and Obese Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary objective
- To investigate pharmacodynamic and pharmacokinetic parameters after s.c. administration
of two different doses (low dose, 0.2 IU/kg and high dose, 0.4 IU/kg) of insulin
glulisine across healthy subjects in 4 different BMI-classes (lean, overweight,
moderately obese, severely obese), using the euglycemic clamp technique with the
Biostator™.
Secondary objective
- To investigate the pharmacodynamic and pharmacokinetic properties after subcutaneous
administration of insulin glulisine in comparison to insulin lispro and to investigate
the safety and tolerability after subcutaneous administration of insulin glulisine in
comparison to insulin lispro.